CHICAGO — Hiroyuki Okuzawa holds an enviable position. The veteran Daiichi Sankyo executive took over as the Japanese ...

New drugs, however heralded, take time to embed into clinical care. Enhertu, the powerful antibody-drug conjugate from ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.